Cancel

Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers

STATEMENT OF NEED Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork...
i3 Health

Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma

STATEMENT OF NEED Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis...
i3 Health

Hitting the Target in HER2-Positive Metastatic Colorectal Cancer

STATEMENT OF NEED An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment...
i3 Health

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu...
i3 Health

Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now! STATEMENT OF NEED Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite...
i3 Health

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident...
i3 Health

Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View

STATEMENT OF NEED Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ...
i3 Health

New Guidance to Diagnose and Treat Tumor-induced Osteomalacia (TIO)

This 30-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose and treat tumor induced osteomalacia (TIO) based on the recently published global guidance document in the Journal of Internal Medicine. This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management...
CheckRare

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ...
i3 Health

Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the...
i3 Health

Obstetrics and Gynecology 2024 - LIVE STREAMING or IN PERSON IN BOSTON, MA

Obstetrics, Infertility, Difficult Deliveries, Adolescent Gynecology, Urogynecology, MIGS, Menopause Management, Reproductive Endocrinology, Gynecologic Oncology in General Practice, and Management of High-Risk Patients The 60th Annual Update: Obstetrics and Gynecology 2024 will be held March 8 " 13, 2024. You can attend online as the course is live streamed, or in person in Boston, MA. All sessions will be recorded and made available to all participants to view online, at your conveni...
Harvard Medical School

Leveraging the Anti-Tumor Activity of the Immune System: Systemic Treatment for Advanced Non-Melanoma Skin Cancers

Target Audience This activity is designed to meet the educational needs of global oncologists, dermatologists, Mohs surgeons, and the multidisciplinary care team who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas. Program Overview This enduring activity will increase the target HCP’s understanding of new immune therapies and clinical trial data for treating patients with advanced NMSCs; ability to identify and manage side effects associate...
Relias LLC

Clinical Endocrinology 2024 - LIVE STREAMING

Clinical Strategies and Comprehensive Updates for State-of-the-Art Endocrine Care Clinical Endocrinology 2024, a live streaming CME program, has been optimized for remote learning. All sessions and workshops will be live streamed and include online, live chat, where participants can pose their specific questions to faculty. All sessions and workshops will be recorded and made available to participants for online viewing, at their convenience, via a course archive. As a participant, you will...
Harvard Medical School

15th Annual Topics in Primary Care

The 15th Annual Topics in Primary Care will focus on updates on common problems encountered in primary care, bringing excellent instructors to provide teaching geared toward learning, retention, and practice change. The conference will have a hybrid format to facilitate both in person and remote learning. We encourage in-person attendance, when possible, for learning and camaraderie. Grand Rounds features Dr. Lauren Weber addressing cardiovascular risk stratification and treatment, answerin...
Virginia Mason Franciscan Health

Pathways to Developing Personalized Treatment Regimens for Patients with Advanced Melanoma

No two patients with advanced melanoma are the same and tailoring treatment is vital. Immerse yourself in this interactive “choose your path” digital algorithm with expert perspectives to assist with the application of new guidelines and treatment options to optimize therapy. Do you have questions about treating patients with advanced melanoma? Do you wonder… • When to use immune checkpoint inhibitors (ICIs), and in which combinations? • How to select among the growing number o...
ACHL

Office Practice of Primary Care Medicine 2024 - LIVE STREAMING

The Comprehensive 2024 Update on Office-Based Primary Care Medicine Taught Live Online by Harvard Medical School's Leading Clinical Faculty Office Practice of Primary Care Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies. OVERVIEW Office Practice of Primary Care Medicine provides comprehensive reviews of the most important recent advances impacting primary care medicine and guidance to assimilate these changes...
Harvard Medical School

Skin Cancer Education for Primary Care

This comprehensive course on skin cancer will help you improve your ability to diagnose and manage skin lesions, the most common of all cancers. Outcome Objectives: As a result of completing this activity, the participant will be better able to: - Understand the biology of ultraviolet radiation and methods to protect the skin. - Demonstrate increased proficiency in the management of potentially malignant skin lesions. - Make early diagnoses of skin cancers, particularly melanoma....
Virtual Lecture Hall (University of Arizona College of Medicine - Tucson)

Pulmonary and Critical Care Medicine 2024 - LIVE STREAMING

Comprehensive Updates for State-of-the-Art Evaluation, Diagnosis, and Treatment This comprehensive live streaming online course, which is among the highest-rated Harvard Medical School CME courses, provides education and updates to optimize your care of patients with: • Sepsis • ARDS • Sarcoidosis • IPF • Bronchiectasis • Cystic fibrosis • Lung nodules • Lung cancer • GERD • Pleural disease • Pneumonia • Tuberculosis • Thromboembolism • Chronic cou...
Harvard Medical School

Real-World Perspectives in Managing CLL Treatment

Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ...
Purdue University College of Pharmacy

The Role of the Clinical Pharmacist in the Management of Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements ...
American Academy of CME

Anesthesiology Update 2024 - LIVE STREAMING or IN PERSON

The Comprehensive 2024 Anesthesiology Update Cardiac, Regional, Office-Based, Thoracic, Obstetric, Neuro, and Pediatric Anesthesiology Update will be held on May 6-10, 2024. You have the option to attend either online as the course is live streamed or in person in Boston, MA. In the past year, there have been a number of very significant clinical changes that affect the practice of anesthesiology. This comprehensive CME program provides a special and timely opportunity for anesthesiolo...
Harvard Medical School

Combining Locoregional and Systemic Therapy for Challenging HCC Cases

Target Audience This educational activity is intended for interventional oncologyists physicians, nurses, and other members of the health care team who care for patients with hepatocellular carcinoma (HCC) Program Overview This activity focuses on challenges in the management of HCC using the latest clinical data supporting locoregional therapy, and on strategies for greater collaboration amongst the multidisciplinary teams in community vs academic settings. Learning Objectives Upon c...
Society of Interventional Oncology and The France Foundation.

Optimizing Transition from Pediatric to Adult Care - LIVE STREAMING

In this special program, faculty from Harvard Medical School, the Brigham Transition Care Team, and the Boston Children’s Hospital BRIDGES Adult Transition Program provide strategies, best practices, and guidance to: • Identify adult care providers and successfully transfer patients with rare or complex health care needs • Assess and improve the efficacy of your current transition processes • Tailor transition strategies to patient age, disease type, and physical/ intellectual capab...
Harvard Medical School

Innovations and New Practices in Internal Medicine 2024 -LIVE STREAMING

The State of the Art in Internal Medicine This program, which is among the highest-rated Harvard Medical School CME courses, provides a comprehensive update of the most important changes now impacting Internal Medicine and guidance on how to incorporate these changes into your clinical practice to improve patient outcomes.. Practical, Fast-Paced, Online Education This live streaming educational experience is fast paced, relevant to the current healthcare environment, and draws upon real...
Harvard Medical School

Graft vs Host Disease: Novel Management Strategies for a Chronic Condition

Target Audience The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD. Program Overview This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and invest...
Med Learning Group

Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes

Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by ...
American Academy of CME

How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r...
ACHL

Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ...
Postgraduate Institute for Medicine and RME Collaborative.

Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a...
Talem Health and RME Collaborative.

Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ...
Postgraduate Institute for Medicine and RME Collaborative.

Gastroenterology 2024 - LIVE STREAMING

The Comprehensive 2024 Gastroenterology Update This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians. Practical, Results-Driven Education Highlights of the 2024 program include: • Updated...
Harvard Medical School

Internal Medicine Comprehensive Review and Update 2024 - LIVE STREAMING

Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties This program, the 64th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care. This program covers the breadth of Internal Medicine subspecialties, including: • Cardiovascular Medicine ...
Harvard Medical School

TOP 10 Early Cancer Detection Queries What You Need to Know About Blood-Based Screening in Primary Care

In this “Top 10 Early Cancer Detection Queries” program, Dr. Mylynda Massart answers the 10 questions most commonly asked by primary care clinicians about blood-based multi-cancer early detection (MCED) tests. Some of the topics addressed are the science behind MCEDs, their accuracy, how MCEDs compare to other screening modalities, and integration of MCED testing into primary care practice.
Integritas Communications

Top 10 COVID-19 Special Population Queries

Even though the COVID-19 pandemic is slowly becoming endemic, there are still certain populations at higher risk of progressing to severe COVID-19 should they become infected with SARS-CoV-2. These include immunocompromised groups, older patients, patients with HIV, disabilities, challenges in social determinants of health, and racial or ethnic minorities. There are treatment considerations for many of these populations, including drug-drug interactions. In this self-directed activity, Drs. Gl...
Integritas Communications

Hot Topics in Blood-based Cancer Screening: Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings

Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25% of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-base...
Integritas Communications

Intensive Review of Nephrology - LIVE STREAMING

With over 70 interactive lectures, case discussions, board preparation sessions, and supplementary lectures, this CME program provides a comprehensive review of state-of-the-art nephrology practices offered by the clinical faculty of Harvard Medical School. It offers accelerated learning for: - Clinicians seeking a practical and comprehensive review that ensures they are up to date across all major areas of nephrology: • The latest options for diagnosis: what to choose, when, and wh...
Harvard Medical School

Hitting The Bullseye in NSCLC

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation ...
Integritas Communications

Clinical Competence in Breast Imaging, Interventions and Management

Clinical Competence in Breast Imaging, Interventions and Management provides a complete tutorial in all modalities, diagnostic strategies and interventional considerations encountered in the modern breast imaging practice. Its fifty cases allow the participant to explore a wide range of benign and malignant disease, with special focus placed on the variety of presentations and patterns of enhancement observed on mammogram, ultrasound, MRI and tomosynthesis. This activity also expounds on the...
Meetings By Mail®

Applying Evolving Targeted Therapy in Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se...
Annenberg Center for Health Sciences at Eisenhower

Nursing and Nutrition: Providing Survival Skills

Nursing and Nutrition: Providing Survival Skills is designed to help nurses provide basic nutritional guidelines for hospitalized patients. Upon completing this course, they will be able to guide patients to a healthy lifestyle that will aid in their recovery. The course includes food do's and dont's as related to specific issues, such as heart failure, cancer treatment, wound care, etc.
Corexcel

LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity

Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho...
Integritas Communications

Nursing Management of Tumor Lysis Syndrome

STATEMENT OF NEED Tumor lysis syndrome (TLS) is an oncological emergency that occurs when massive tumor lysis causes the rapid release of intracellular components into the bloodstream. Electrolyte imbalances characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, and even death. Current advances in cancer therapies can increase the incidence of TLS; therefore, identification of patien...
i3 Health

Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.
Annenberg Center for Health Sciences at Eisenhower

PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team

Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati...
University of Cincinnati

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ...
ACHL

Answering The Call in Nonadvanced Systemic Mastocytosis

Target Audience The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM). Program Overview Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, and complicated therapeutic paradigm. In this unique and engaging Call-a-Colleague program, a panel of...
Integritas Communications

Can You Compete in Early Cancer Detection

This activity is an informative and engaging presentation about blood-based multi-cancer early detection MCED screening in the primary care setting. Drs. Massart, Vega, and Whittington will provide key data related to current gaps in cancer surveillance, the science and data behind MCEDs, and information on how to implement MCED screening into practice.
Integritas Communications

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa...
ACHL

Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams

An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity mana...
Annenberg Center for Health Sciences

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map